The AIDS drug assistance programs, coverage of HIV-related medications

Annals of Pharmacotherapy

Volumn 35, Issue 2, 2001, Pages 155-166

  Smith, S R ^a   Buchanan, R J ^a  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

AIDS; Drug assistance; Drug funding; HIV

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BUDGET; DRUG FORMULARY; DRUG PROGRAM; HEALTH CARE ACCESS; HEALTH CARE FINANCING; HEALTH INSURANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LOWEST INCOME GROUP; PHARMACY BENEFIT MANAGER; PRIORITY JOURNAL;

EID: 0035145777     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.10077     Document Type: Article

References (21)

1. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators
2. Natural history of HIV infection in the era of combination antiretroviral therapy
3. Changes in HIV and AIDS epidemiology from new generation therapy
4. Natural history of opportunistic disease in an HIV-infected urban clinical cohort
5. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions
6. Drug assistance programs funded by Title II of the Ryan White CARE Act: A survey of the states
7. The Ryan White CARE Act: The states' allocation of Title II funding among programs
8. State implementation of the AIDS drug assistance programs
9. Risks for HIV infection among persons residing in rural areas and small cities - Selected sites, southern United States, 1995-1996
10. Southern states have largest number of AIDS cases
11. Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection
12. Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study
13. Immune-based therapies in the management of HIV-infected patients
14. Increasing survival in AIDS patients with cytomegalovirus retinitis treated with combination antiretroviral therapy including HIV protease inhibitors
15. Effect of highly active antiretroviral therapy on the incidence of HIV-associated malignancies at an urban medical center
16. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus